These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 26982510)

  • 1. The safety of monoclonal antibodies for treatment of colorectal cancer.
    Berger MD; Lenz HJ
    Expert Opin Drug Saf; 2016 Jun; 15(6):799-808. PubMed ID: 26982510
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Monoclonal antibodies in the treatment of metastatic colorectal cancer: a review.
    Tol J; Punt CJ
    Clin Ther; 2010 Mar; 32(3):437-53. PubMed ID: 20399983
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epidermal growth factor receptor monoclonal antibodies for the treatment of metastatic colorectal cancer.
    Jean GW; Shah SR
    Pharmacotherapy; 2008 Jun; 28(6):742-54. PubMed ID: 18503402
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and efficacy of panitumumab therapy after progression with cetuximab: experience at two institutions.
    Saif MW; Kaley K; Chu E; Copur MS
    Clin Colorectal Cancer; 2010 Dec; 9(5):315-8. PubMed ID: 21208847
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The safety and efficacy of ramucirumab for the treatment of metastatic colorectal cancer.
    Diaz-Serrano A; Riesco-Martinez MC; Garcia-Carbonero R
    Expert Rev Anticancer Ther; 2016 Jun; 16(6):585-95. PubMed ID: 27144874
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Successful desensitization with cetuximab after an infusion reaction to panitumumab in patients with metastatic colorectal cancer.
    Saif MW; Syrigos KI; Hotchkiss S; Shanley J; Grasso J; Ferencz TM; Syrigos K; Shah MM
    Cancer Chemother Pharmacol; 2009 Dec; 65(1):107-12. PubMed ID: 19415280
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Panitumumab safety for treating colorectal cancer.
    Stremitzer S; Sebio A; Stintzing S; Lenz HJ
    Expert Opin Drug Saf; 2014 Jun; 13(6):843-51. PubMed ID: 24766434
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The use of EGFR inhibitors in colorectal cancer: is it clinically efficacious and cost-effective?
    Lien K; Berry S; Ko YJ; Chan KK
    Expert Rev Pharmacoecon Outcomes Res; 2015 Feb; 15(1):81-100. PubMed ID: 25400031
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetic and pharmacodynamic evaluation of panitumumab in the treatment of colorectal cancer.
    Lo L; Patel D; Townsend AR; Price TJ
    Expert Opin Drug Metab Toxicol; 2015; 11(12):1907-24. PubMed ID: 26572750
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical use of anti-epidermal growth factor receptor monoclonal antibodies in metastatic colorectal cancer.
    Patel DK
    Pharmacotherapy; 2008 Nov; 28(11 Pt 2):31S-41S. PubMed ID: 18980550
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer.
    Van Cutsem E; Peeters M; Siena S; Humblet Y; Hendlisz A; Neyns B; Canon JL; Van Laethem JL; Maurel J; Richardson G; Wolf M; Amado RG
    J Clin Oncol; 2007 May; 25(13):1658-64. PubMed ID: 17470858
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Relationship between the Incidence of Hypomagnesemia and Acneiform Rash and the Therapeutic Effect of Anti-EGFR Monoclonal Antibody in Patients with Metastatic Colorectal Cancer].
    Fujii H; Iihara H; Ishihara M; Matsuhashi N; Takahashi T; Yoshida K; Itoh Y
    Gan To Kagaku Ryoho; 2016 Feb; 43(2):229-33. PubMed ID: 27067688
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-EGFR monoclonal antibodies for treatment of colorectal cancers: development of cetuximab and panitumumab.
    You B; Chen EX
    J Clin Pharmacol; 2012 Feb; 52(2):128-55. PubMed ID: 21427284
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment with panitumumab after a severe infusion reaction to cetuximab in a patient with metastatic colorectal cancer: a case report.
    Heun J; Holen K
    Clin Colorectal Cancer; 2007 May; 6(7):529-31. PubMed ID: 17553202
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SPIRITT: A Randomized, Multicenter, Phase II Study of Panitumumab with FOLFIRI and Bevacizumab with FOLFIRI as Second-Line Treatment in Patients with Unresectable Wild Type KRAS Metastatic Colorectal Cancer.
    Hecht JR; Cohn A; Dakhil S; Saleh M; Piperdi B; Cline-Burkhardt M; Tian Y; Go WY
    Clin Colorectal Cancer; 2015 Jun; 14(2):72-80. PubMed ID: 25982297
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Monoclonal antibodies therapies for colorectal cancer: cétuximab, panitumumab and bevacizumab].
    Piront P; Van Daele D; Belaiche J; Polus M
    Rev Med Liege; 2009; 64(5-6):274-8. PubMed ID: 19642458
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chemotherapy with targeted agents for the treatment of metastatic colorectal cancer.
    Köhne CH; Lenz HJ
    Oncologist; 2009 May; 14(5):478-88. PubMed ID: 19411318
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-EGFR monoclonal antibodies in metastatic colorectal cancer: time for an individualized approach?
    Fakih M
    Expert Rev Anticancer Ther; 2008 Sep; 8(9):1471-80. PubMed ID: 18759698
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Panitumumab in metastatic colorectal cancer.
    Hocking CM; Townsend AR; Price TJ
    Expert Rev Anticancer Ther; 2013 Jul; 13(7):781-93. PubMed ID: 23802848
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Integration of panitumumab into the treatment of colorectal cancer.
    Gravalos C; Cassinello J; García-Alfonso P; Jimeno A
    Crit Rev Oncol Hematol; 2010 Apr; 74(1):16-26. PubMed ID: 19616446
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.